For standard-risk multiple myeloma patients with renal problems, Darzalex Faspro (daratumumab and hyaluronidase-fihj) can be considered for maintenance therapy post-BMT. However, the best maintenance therapy should be personalized based on individual health conditions and response to treatment.

Key points
- Darzalex Show Full Answer

For standard-risk multiple myeloma patients with renal problems, Darzalex Faspro (daratumumab and hyaluronidase-fihj) can be considered for maintenance therapy post-BMT. However, the best maintenance therapy should be personalized based on individual health conditions and response to treatment.

Key points:
- Darzalex Faspro: Effective and convenient subcutaneous administration.
- Renal Monitoring: Regular monitoring of kidney function is essential.
- Consultation: Always discuss with your healthcare provider to tailor the best maintenance therapy for your specific condition.

For more detailed guidance, please consult your oncologist.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

6 Facts About Myeloma Maintenance Therapy | MyMyelomaTeam

Darzalex (Daratumumab) for Myeloma | MyMyelomaTeam